IFNL4 polymorphism as a predictor of chronic hepatitis C treatment efficiency in Ukrainian patients

Kucherenko A., Pampukha V., Romanchuk K., Chernushyn S., Bobrova I., Moroz L., Livshits L.

SUMMARY. The aim of this study was to examine association between IFNL4 gene ss469415590 and treatment efficiency in group of Ukrainian PEG-interferon/ribavirin-treated chronic hepatitis C patients. Study group consisted of 92 unrelated hepatitis C virus genotype 1 mono-infected patients: case group - 29 patients with late or absent virological response; control group - 63 patients with sustained virological response. Study material was genomic DNA. Genotyping was performed using amplification-refractory mutation system PCR. Statistical analysis was performed using GenePop and OpenEpi statistical packages. Obtained results show that ss469415590 ΔG/ΔG genotype is associated with poor virological response (OR = 3.62; CI 95%: 1.12-11.67) in PEG-interferon/ribavirin-treated chronic hepatitis C patients from Ukraine.

Key words: IFNL4, pharmacogenetic marker, hepatitis C, treatment efficiency

Tsitologiya i Genetika 2016, vol. 50, no. 5, pp. 79-84

E-mail: kucherenko.a.m gmail.com

Kucherenko A., Pampukha V., Romanchuk K., Chernushyn S., Bobrova I., Moroz L., Livshits L. IFNL4 polymorphism as a predictor of chronic hepatitis C treatment efficiency in Ukrainian patients, Tsitol Genet., 2016, vol. 50, no. 5, pp. 79-84.

In "Cytology and Genetics":
A. M. Kucherenko, V. M. Pampukha, K. Yu. Romanchuk, S. Yu. Chernushyn, I. A. Bobrova, L. V. Moroz, L. A. Livshits IFNL4 polymorphism as a predictor of chronic hepatitis C treatment efficiency in Ukrainian patients, Cytol Genet., 2016, vol. 50, no. 5, pp. 330–333
DOI: 10.3103/S0095452716050066